Neumonitis aguda en un paciente con enfermedad de Still del adulto tras tratamiento con tocilizumab con buena respuesta a anakinra

Gómez, Clara Sangüesa; Robles, Bryan Josué Flores; Chinarro, B. Jara; Malpartida, María Espinosa; Mateos, C. Barbadillo

doi:10.1016/j.reuma.2015.08.007

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[53,56] Case reports have been published describing organising pneumonia, acute pneumonitis, as well as exacerbation of combined pulmonary fibrosis and emphysema syndrome associated with use of tocilizumab. [57][58][59] Interference with signal transduction pathways: tyrosine kinase inhibitors Tyrosine kinases are intracellular enzymes that transmit signals by transferring phosphate groups to tyrosine residues on cytoplasmic proteins or the intracellular domains of transmembrane receptors. [60,61] They are classified as targeted synthetic DMARDs.…”

Section: Tumour Necrosis Factor Inhibitorsmentioning

confidence: 99%

Adverse effects of biologic anti-inflammatory agents on the respiratory system: A review

Joseph

Tintinger

Ker

et al. 2021

Afr J Thorac Crit Care Med

View full text Add to dashboard Cite

The therapy of autoimmune rheumatological conditions has undergone significant changes with the introduction of biologic antiinflammatory agents including cytokine antagonists and agents that interfere with the function of T and B cells or those that inhibit intracellular enzymes such as Janus kinase (JAK). Although useful to control inflammation, these agents may be associated with druginduced lung disease, which may be difficult to differentiate from pulmonary disorders caused by the underlying autoimmune diseases. This review aims to provide a description of lung disease, both infectious and non-infectious, that may be induced by the administration of biologic anti-inflammatory agents with emphasis on inhibitors of tumour necrosis factor, interleukin-1, interleukin-6 and JAK.

show abstract